A PHASE I DOSE ESCALATION AND EXPANSION STUDY OF INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：1

作者：

Eigentler, Thomas ^{[1
]}

Heinzerling, Lucie ^{[2
]}

Krauss, Juergen ^{[3
]}

Weishaupt, Carsten ^{[4
]}

Mohr, Peter ^{[5
]}

Ochsenreither, Sebastian ^{[6
]}

Terheyden, Patrick ^{[7
]}

Martin-Liberal, Juan ^{[8
]}

Oliva, Marc ^{[8
]}

Lebbe, Celeste ^{[9
]}

Fluck, Michael ^{[10
]}

Brossart, Peter ^{[11
]}

Trigo Perez, Jose Manuel ^{[12
]}

Bauernfeind, Franz-Georg ^{[11
]}

Kays, Sarah-Katharina ^{[13
]}

Seibel, Tobias ^{[13
]}

Schoenborn-Kellenberger, Oliver ^{[13
]}

Stosnach, Claudia ^{[13
]}

Daehling, Angelika ^{[13
]}

Schmitt-Bormann, Beate ^{[13
]}

Gnad-Vogt, Ulrike ^{[13
]}

机构：

[1] Univ Med Ctr Tubingen, Tubingen, Germany

[2] Univ Erlangen Nurnberg, Erlangen, Germany

[3] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[4] Univ Munster, Munster, Germany

[5] Elbe Med Ctr, Buxtehude, Germany

[6] Charite Campus Benjamin Franklin, Berlin, Germany

[7] Univ Lubeck, Lubeck, Germany

[8] Hosp Duran & Reynals, Barcelona, Spain

[9] Hop St Louis, Paris, France

[10] Fachklin Hornheide, Munster, Germany

[11] Univ Clin Bonn, Bonn, Germany

[12] Hosp Clin V de la Victoria, Malaga, Spain

[13] CureVac AG, Tubingen, Germany

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0800

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

800

引用

页码：A478 / A479

页数：2

共 50 条

[31] IBI110 (anti-LAG-3 mAb) as a single agent or in combination with sintilimab (anti-PD-1 mAb) in patients with advanced solid tumors: Updated results from the phase Ia/Ib dose-escalation study
Xu, Nong
Mao, Chenyu
Qian, Jiong
Zheng, Yulong
Jiang, Haiping
Gao, Yuan
Xiao, Cheng
Xiong, Anwen
Li, Wei
He, Yayi
Ren, Shengxiang
Wang, Lei
Yu, Jia
Zhu, Jun
Liu, Ying
Zhou, Caicun
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignancies
Ma, Vincent T.
Milhem, Mohammed M.
Hidalgo, Manuel
Shields, Anthony F.
Segar, Jennifer Margaret
Khalil, Maya
Davis, Andrew A.
Verschraegen, Claire F.
Wong, Deborah J. L.
Schilder, Russell J.
Gao, Xin
Powderly, John D., II
Jiang, Yixing
Aggarwal, Rahul Raj
Awan, Farrukh Tauseef
McKean, Meredith
Chow, Warren Allen
Yao, Sheng
Keegan, Patricia
Naing, Aung
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[33] A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors
Shapiro, Geoffrey
Barve, Minal A.
Bhave, Manali A.
Subbiah, Vivek
Uttamsingh, Shailaja
Sharma, Keerti
Andrianova, Lana
Patnaik, Amita
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[34] Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
Coward, Jermaine
Mislang, Anna Rachelle Austria
Frentzas, Sophia
Lemech, Charlotte Rose
Nagrial, Adnan
Jin, Xiaoping
Li, Baiyong
Wang, Zhongmin Maxwell
Kwek, Kon Yew
Xia, Yu
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] A phase I dose escalation and pharmacodynamic study of weekly administered AlbuleukinTM in patients with advanced solid tumors.
Agarwala, SS
Bukowski, RM
Kirkwood, J
Weiss, P
Olencki, T
Grzegorewski, KJ
Melder, R
Fox, RA
Herpst, JM
Gallant, G
CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6230S - 6231S
[36] A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors
Liu, Dan
Gong, Jifang
Zhang, Jian
Shu, Yongqian
Wu, Hao
Liu, Tianshu
Xu, Yanhua
Zhang, Lijia
Li, Min
Hu, Xichun
Shen, Lin
INVESTIGATIONAL NEW DRUGS, 2025, : 250 - 261
[37] A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
Segal, Neil Howard
Hodi, F. Stephen
Sanborn, Rachel E.
Gajewski, Thomas
Wolchok, Jedd D.
Urba, Walter John
Fox, Bernard A.
Topallan, Suzanne Louise
Pardoll, Drew M.
Kollia, Georgia
McDonald, Dan
Kim, Su Young
Sharfman, William Howard
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[38] Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
Liu, Rujiao
Li, Wenhua
Meng, Yanchun
Gao, Shuiping
Zhang, Jian
Hu, Xichun
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[39] Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
Patnaik, Amita
Kang, Soonmo Peter
Tolcher, Anthony W.
Rasco, Drew Warren
Papadopoulos, Kyriakos P.
Beeram, Muralidhar
Drengler, Ronald
Chen, Cong
Smith, Lon
Perez, Crystal
Gergich, Kevin
Lehnert, Manfred
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[40] Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
Huang, Jing
Mo, Hongnan
Wu, Dawei
Chen, Xuelian
Ma, Lanying
Lan, Bo
Qu, Dong
Yang, Qing
Xu, Binghe
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →